Articles & videos

The flexibility of 3D printing can enable more personalized pharmaceutical products than traditional manufacturing. We embarked on a study to assess the stability of nanoformed piroxicam in 3D printable ink and whether dose control could be achieved. Explore the journey of our piroxicam nanoparticles from nanoformed powder to 3D printable ink in this poster.

Our CEO, Prof. Edward Hæggström was featured in the PODD 2021 newsletter where he discussed the exciting developments at Nanoform and the market trends driving the innovation. Edward also delved into the collaborations and partnerships adding value to Nanoform’s nanoparticle engineering technologies.

In the July 2021 issue of ONDrugDelivery, Niklas Sandler and Thomas West consider the technological advances in nanoparticle engineering that can improve the bioavailability and delivery of oral therapeutics.

Overcoming Drug Development Challenges with Nanotechnology: Piroxicam, a commercially available non-steroidal anti-inflammatory drug, was nanoformed as a model compound to demonstrate the potential benefits of our CESS(R) nanoforming technology for improving solubility, dissolution and in vivo absorption.

Our CTO Niklas Sandler, and Pharmaceutical Development Manager Satu Lakio explain how our nanoparticle engineering technology is revolutionizing oral drug delivery by enhancing solubility and bioavailability.

Our CEO Edward Hæggström, CFO Albert Hæggström, and CCO Christian Jones present an overview of our nanoforming platform technology at Avanza Börsdag.

A record of the conference call held to discuss Nanoform’s initiation of the first human trial of a drug candidate nanoformed using our proprietary CESS® technology.

Nanoform scientists outline how our innovative CESS® technology can help overcome the obstacles many drug candidates face when trying to make it through clinical trials.

Our CTO, Niklas Sandler, and Pharmaceutical Development Manager, Satu Lakio, discuss the advantages of our nanoparticle engineering technology in oral drug development and delivery by boosting solubility and bioavailability.

Our CCO, Christian Jones, discusses the launch our US subsidiary and the extension our partnership with Orion Corporation with Business Trends Magazine.

Nanoform CEO Edward Haeggström and CFO Albert Haeggström discussed the benefits of our cutting-edge nanoforming technology for improving efficiency in Pharma and increasing the rate of drug approval for market with CHEManager.

In this brochure we share our story, explaining how our unique nanoforming services, including our game-changing CESS® technology, can provide solutions to drug development challenges in Pharma.

Our CBO, Dr. Gonçalo Rebelo de Andrade, discusses with Chemicals Knowledge Hub magazine how our nanoforming technology can improve efficiency in the pharmaceutical industry by creating new avenues for drug delivery.

Our CCO, Christian Jones, shared his insights with The Medicine Maker into how our nanoforming technology can improve efficiency and create new opportunities for drug development.

Our CTO, Niklas Sandler, examines the importance of technological innovation for treating age-related diseases in Chemistry World’s Future of Pharma digital supplement.

Our scientists discuss the advantages of applying a multidisciplinary approach to Pharma innovation in the Chemistry World – Voices in Chemistry digital supplement.

Our CTO, Niklas Sandler, discusses the growing demand for nanoformed drug particles and the advantages of our proprietary nanoforming technology offers with Cleanroom Technology Magazine.

Our Head of AI, Jukka Corrander, spoke to Technology Networks about our innovative use of sparse data AI with our proprietary STARMAP™ technology.

Our CBO, Gonçalo Rebelo de Andrade, discusses the advantages offered by our excipient-free nanoforming technology with BioPharm International.

Our CTO, Niklas Sandler, explains how our innovative use of nanoforming technology and sparse-data AI is being used to enhance drug molecules in the European Pharmaceutical Manufacturer.